The oral fluorinated pyrimidines

Investigational New Drugs

Volumn 19, Issue 1, 2001, Pages 41-59

  De Bono, J S ^a   Twelves, C J ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

5 Fluorouracil; Capecitabine; Ethinyluracil; Oral; Prodrug; S1; UFT

Indexed keywords

5 ETHYNYLURACIL; BMS 247616; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; EMITEFUR; ENZYME INHIBITOR; FLUOROURACIL; PRODRUG; PYRIMIDINE DERIVATIVE; S1; TEGAFUR; UFT; UNCLASSIFIED DRUG; URACIL;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; HEADACHE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CLINICAL TRIALS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; NEOPLASMS; OXIDOREDUCTASES; PRODRUGS; TEGAFUR; URACIL;

EID: 0035098362     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006404701008     Document Type: Review

References (112)

1. Oral chemotherapy: Rationale and future directions
2. New agents for colorectal cancers: Oral fluorinated pyrimidines and oxaliplatin
3. Fluorinated pyrimidine. A new class of tumor inhibitory compounds
4. 5-Fluoropyrimidines
5. Relationship between fluorouracil systemic exposure and tumor response and patient survival
6. Cellular basis for the inefficacy of 5FU in human colon carcinoma
7. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma
8. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study
9. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: Evolution of a regimen
10. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer
11. Fluorouracil combined with the pure (6S)stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: A phase I-II study
12. Influence of sex and age on fluorouracil clearance
13. Regional chemotherapy for colorectal liver metastases: A Phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases
14. Clinical impact of pharmacokinetically guided dose adaptation of 5-fluorouracil: Results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas
15. Multicentric randomized trial in advanced colorectal cancer comparing weekly treatment of intensified 5-fluorouracil and folinic acid with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area
16. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis
17. Familial pyrimidinernia and pyrimidinuria associated with severe fluorouracil toxicity
18. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracilinduced toxicity
19. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome
20. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
21. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
22. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency
23. Population study of dihydropyrimidine dehydrogenase in cancer patients
24. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
25. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
26. Clinical pharmacology of 5-fluorouracil
27. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
28. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: Possible relevance to fluoropyrimidine chemotherapy
29. Enzymes of uracil catabolism in normal and neoplastic human tissues
30. Spector T5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
31. 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo
32. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase
33. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil
34. Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation
35. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
36. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors
37. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
38. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells
39. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in routine intestinal epithelia
40. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins
41. Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy
42. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
43. Thymidylate synthese mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
44. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
45. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
46. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites
47. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil
48. Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma
49. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
50. Thymidine phosphorylase is angiogenic and promotes tumor growth
51. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
52. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas
53. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy
54. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma
55. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors
56. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
57. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
58. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
59. Design of a novel oral fluoropyrimidine carbarnate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
60. Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer
61. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
62. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors
63. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
64. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
65. A mat-fix designed Phase I dose finding and pharmacokinetic study of the combination of capecitabine (Xeloda) and docetaxel (Taxotere) in patients with advanced solid tumors
66. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
67. Tumor selectivity of capecitabine following oral administration in colorectal cancer patients
68. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
69. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
70. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
71. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
72. A randomised Phase II study of Xeloda Im (capecitabine) in patients with advanced colorectal cancer
73. Multi-center Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
74. A randomized Phase II study of xeloda (Capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged 55 years
75. A randomized Phase II study of xeloda TM (Capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
76. A Phase III trial (SO14796) of xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer
77. A Phase III trial of XELODA™ (Capecitabine) in previously untreated advanced/metastatic colorectal cancer
78. Cancer report on nationwide pooled data and cohort investigation in UFT Phase II study
79. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958)
80. Uracil-ftorafur: An oral fluoropyrimidine active in colorectal cancer
81. Uracil-tegafur in gastric carcinoma: A comprehensive review
82. Phase I trials of Uracil-Tegafur (UFT) using 5 and 28 day administration schedules: Demonstration of schedule-dependent toxicities
83. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil
84. A Phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer
85. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-Day schedule
86. Phase I trial of Uracil-Tegafur (UFT) plus oral leucovorin: 28-Day schedule
87. Phase II trial of UFT in advanced colorectal and gastric cancer
88. Phase II trial of Uracil and Tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
89. Efficacy of oral Tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A Phase II study
90. Phase II trial of uracil/Tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma
91. Toxicity profile of UFT (Uracil-Tegafur) observed in a Phase III randomized comparison of surgical adjuvant chemotherapy with UFT versus CMF in high-risk node negative breast cancer patients
92. Impact of surgical adjuvant chemotherapy on quality of life (QOL) of patients with breast cancer - A Phase III randomized trial comparing UFT (Uracil/Tegafur) with CMF in high-risk node negative patients
93. Randomized comparative study of ORZEL® (oral Uracil/Tegafur (UFT™) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
94. Multicenter Phase III study of 5-fluorouracil (5-FU) or UFF™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer
95. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S1) against human colon carcinoma orthotopically implanted into nude rats
96. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
97. Antitumor activity and low intestinal toxicity of S1, a new formulation of oral tegafur, in experimental tumor models in rats
98. Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU) based anti-neoplastiG agent
99. Late Phase II study of a novel oral fluoropyrimidine anti-cancer drug 3-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric; cancer patients
100. Late Phase II study of S- 1 in patients with advanced colorectal cancer in Japan
101. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative
102. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil clehydrogenase
103. Antitumor activity, of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration
104. New anti-cancer drugs for gastrointestinal cancers
105. Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues
106. Spector. T5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
107. 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma
108. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
109. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase activity in colorectal tumors
110. 2 × 2 daily) as firstline chemotherapy in patients with advanced breast cancer: A Phase II study
111. Eniluracil/5FU in anthracycline and taxane refractory breast cancer
112. A Phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer